STOCK TITAN

ABBVIE INC. - ABBV STOCK NEWS

Welcome to our dedicated page for ABBVIE news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on ABBVIE stock.

AbbVie Inc. (NYSE: ABBV), headquartered in North Chicago, Illinois, is a leading pharmaceutical company ranked 6th on the list of largest biomedical companies by revenue. Known for their commitment to delivering innovative medicines, AbbVie focuses on several key therapeutic areas including immunology, oncology, neuroscience, and eye care. Their portfolio also includes products and services in aesthetics through Allergan Aesthetics, a company they acquired in 2020.

AbbVie’s flagship product, Humira (adalimumab), generated $21 billion in revenue in 2022, accounting for 37% of the company's total revenues. Humira is approved for the treatment of various autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. Beyond Humira, AbbVie has developed other notable immunology drugs, including Skyrizi and Rinvoq, which have shown strong market performance.

In the oncology sector, AbbVie markets Imbruvica and Venclexta, which are critical in treating hematological malignancies. The acquisition of Allergan also brought in new products in aesthetics, including Botox, which is not only a cosmetic treatment but also used therapeutically for various conditions.

AbbVie's research and development efforts are robust, with numerous clinical trials ongoing across its therapeutic areas. Recent achievements include positive topline results from the LEVEL UP study, which demonstrated the efficacy of Rinvoq in treating atopic dermatitis. Financially, AbbVie continues to perform well, reporting first-quarter 2024 revenues of $12.310 billion, a 0.7% increase from the previous year.

Strategic partnerships are also a cornerstone of AbbVie’s growth strategy. Recent collaborations include an agreement with Gilgamesh Pharmaceuticals to develop neuroplastogens for psychiatric disorders and a partnership with Landos Biopharma to enhance their immunology portfolio.

AbbVie remains focused on its mission to address serious health issues and improve patient outcomes globally, leveraging its comprehensive pipeline and innovative solutions in biomedical research.

Rhea-AI Summary

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), will present four abstracts at the virtual American Society for Dermatologic Surgery (ASDS) meeting from October 9-11, 2020. Key presentations include:

  • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers, presented by Joely Kaufman on October 10 at 11:27 a.m..
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA, presented by Joel L. Cohen on October 11 at 10:27 a.m..

The abstracts will focus on safety, efficacy, and patient satisfaction related to aesthetic treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
-
Rhea-AI Summary

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced its agreement to acquire Luminera, an Israel-based aesthetics company specializing in dermal fillers. This acquisition will enhance Allergan's existing JUV DERM® filler portfolio with Luminera's innovative products, including the differentiated HArmonyCa filler. The deal aims to strengthen Allergan Aesthetics' position in the global aesthetics market, providing new offerings for healthcare professionals and patients. The full dermal filler portfolio will also support international development opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
-
Rhea-AI Summary

AbbVie will announce its third-quarter 2020 financial results on October 30, 2020, before market opening. A live webcast of the earnings conference call is scheduled for 8 a.m. Central time. The event can be accessed through AbbVie's Investor Relations website, with an archived version available later that day. AbbVie is dedicated to developing innovative medicines for serious health issues in various therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences earnings
Rhea-AI Summary

AbbVie (NYSE: ABBV) announced its participation at the 2020 Virtual Migraine Trust International Symposium from October 3-9, showcasing findings from 15 clinical trials. Key highlights include new data from the Phase 3 ADVANCE trial for atogepant, a CGRP receptor antagonist aimed at migraine prevention. The symposium will feature oral presentations on October 7, outlining atogepant’s efficacy and safety, as well as research on BOTOX® and UBRELVY®. The ongoing efforts reflect AbbVie's commitment to advancing migraine treatment amid a significant global health burden affecting over 1 billion individuals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
Rhea-AI Summary

AbbVie announced that the FDA has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational monoclonal antibody targeting spinal cord injury. Elezanumab aims to promote neuronal regeneration by inhibiting repulsive guidance molecule A (RGMa) and is currently in a phase 2 study. The company is partnering with Shirley Ryan AbilityLab and MC10 for a pilot study to optimize treatment approaches. These designations highlight AbbVie's commitment to addressing serious medical conditions and potentially expediting the development of new therapies for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary

Allergan Aesthetics, part of AbbVie, has announced actress Malin Akerman as the first U.S. ambassador for its body contouring portfolio, which includes CoolSculpting® and CoolTone™. Both treatments cater to non-surgical fat reduction and muscle toning. Akerman has personally benefited from these procedures, targeting stubborn fat and enhancing muscle strength. With over 4 million people considering non-invasive body contouring, the partnership aims to educate consumers on these options. Special promotional gift cards are available for CoolSculpting and CoolTone treatments until the end of 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
none
Rhea-AI Summary

AbbVie (NYSE: ABBV) will present findings from numerous studies, including the DYSCOVER study on DUODOPA® and advanced Parkinson's disease, during the 2020 International Congress of Parkinson's Disease and Movement Disorders, from September 12-16. The 12-week DYSCOVER study is the first to compare DUODOPA's efficacy against optimized medical treatment on dyskinesia, an involuntary movement symptom. Additionally, data on ABBV-951, a new treatment for advanced PD, will also be showcased. Overall, 18 abstracts will be presented, highlighting AbbVie's commitment to addressing Parkinson's disease challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
conferences
-
News
Rhea-AI Summary

AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.18 per share, payable on November 16, 2020, to stockholders of record as of October 15, 2020.

Since its inception, AbbVie has increased its dividend by 195% and is part of the S&P Dividend Aristocrats Index, recognizing companies with a history of annual dividend increases over 25 years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
dividends
-
Rhea-AI Summary

AbbVie will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 10 a.m. Central time. CEO Richard A. Gonzalez will present, and the session will be available via a live audio webcast on AbbVie's Investor Relations website, with an archived edition accessible later that day.

AbbVie aims to deliver innovative medicines across key therapeutic areas, including immunology, oncology, and neuroscience, and has a commitment to address serious health challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
Rhea-AI Summary

AbbVie has submitted applications to the FDA and EMA for RINVOQ (upadacitinib) to treat active ankylosing spondylitis. This selective JAK inhibitor aims to address significant treatment gaps for patients suffering from this debilitating condition. The FDA application is backed by the SELECT-AXIS 1 Phase 2/3 trial, which showed that 52% of patients on RINVOQ met the treatment endpoint compared to 26% on placebo (p<0.001). RINVOQ previously gained approval for rheumatoid arthritis, but its safety and efficacy for ankylosing spondylitis remain unestablished. Innovation in this area is crucial given the limited options available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
none

FAQ

What is the current stock price of ABBVIE (ABBV)?

The current stock price of ABBVIE (ABBV) is $166.28 as of November 18, 2024.

What is the market cap of ABBVIE (ABBV)?

The market cap of ABBVIE (ABBV) is approximately 293.7B.

What is AbbVie's primary product?

AbbVie's primary product is Humira (adalimumab), which generated $21 billion in revenue in 2022.

What are the key therapeutic areas AbbVie focuses on?

AbbVie focuses on immunology, oncology, neuroscience, and eye care.

What significant achievement did AbbVie report in their research efforts?

AbbVie reported positive results from the LEVEL UP study, demonstrating the efficacy of Rinvoq in treating atopic dermatitis.

Who are AbbVie's notable partners?

AbbVie has strategic partnerships with companies like Gilgamesh Pharmaceuticals and Landos Biopharma.

What are some of AbbVie's key oncology products?

Key oncology products include Imbruvica and Venclexta.

How did AbbVie perform financially in the first quarter of 2024?

AbbVie reported first-quarter 2024 revenues of $12.310 billion, a 0.7% increase from the previous year.

What products did AbbVie acquire through Allergan?

Through Allergan, AbbVie acquired products in aesthetics, including Botox.

What is AbbVie's mission?

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues and improve patients' lives globally.

What percentage of revenue did Humira contribute in 2022?

Humira contributed 37% of AbbVie's total revenues in 2022.

Where is AbbVie headquartered?

AbbVie is headquartered in North Chicago, Illinois.

ABBVIE INC.

NYSE:ABBV

ABBV Rankings

ABBV Stock Data

293.72B
1.77B
0.09%
73.43%
0.92%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NORTH CHICAGO